. Natural products were also a great source of trypanocidal lead compounds (9 patents). A few patents claiming for compounds with antitrypanosomal activity but disclosing no specific target were also encountered.
Two species of trypanosomes are responsible of the chronic and acute form of HAT respectively, T. brucei gambiense and T. b. rhodesiense, whereas other species (T.
b. brucei, T. congolense and T. vivax) cause animal trypanosomiasis (Nagana) in cattle.
HAT is a resurgent disease in sub-Saharan Africa where it had almost disappeared in the 1960's following the systematic screening and treatment of millions of people at risk.
Unfortunately, active population screening declined in the latter part of the twentieth century and the disease has re-emerged as a major health problem in recent years [2] .
HAT is a daily threat to more than 60 Despite many similarities between African and American trypanosomes, there are crucial differences, such as an intracellular existence for T. cruzi in the mammalian host whereas T. brucei remains exclusively extracellular [1] . These divergences have to be taken into account for drug design since chemotherapeutic agents meant to kill T. cruzi intracellular amastigotes will have to cross several cellular membranes to get to their target and drugs targeting the CNS stage of sleeping sickness must be able to cross the BBB. The rational approach to drug design has been applied to trypanosomes as these parasites have a number of unusual biochemical pathways [13] . However, only a small proportion of these patents displayed specific data of biological activity against these parasites. A few patents published in 2002 and claiming anti-T.
cruzi activity which were previously reviewed by Urbina [27] were not included in this
paper. This review is organised in three sections: in the first place, and representing two third of the entries, are the patents referring to specific drug targets such as proteases In their search for cathepsin K inhibitors, SmithKline Beecham Corp. published several patents describing the syntheses and use of peptidomimetics based on an azepine [201, 202, 203, 204, 205] or thiazepane [206] template. As a whole, about 500
new compounds were prepared and tested as cathepsin K inhibitors and claimed to be useful against different parasitic diseases including trypanosomiasis. However, only two patents [201, 204] reported specific biological data. Four compounds had in vitro K i values of 0.3 nM (1, Figure 2 and Table 1 ) to 1.8 nM against human Cathepsin K and values of 69 to 926 nM against Cathepsin L, Cathepsin S and Cathepsin B when tested in protease catalytic activity assays [201] . The other patent disclosed the inhibition by 4-aminoazepan-3-one derivatives of seven parasitic proteases, including cruzain, rhodesain, falcipain, leishmania B and L and schistosoma B1 and B2 enzymes. Among 222 compounds tested, 43 had a K i value < 5 nM against cruzain and 79 had a K i < 5 nM against rhodesain. The most potent CPI against rhodesain and cruzain were the 1-(pyridin-2-ylsulfonyl)azepan-3-one derivatives 2 and 3, respectively (Table 1 ). Other peptidomimetics useful as CPI were reported by NAEJA Pharmaceuticals Inc. [207] .
The preparation of 22 dihydropyrimidine derivatives was illustrated and the in vitro rat cathepsin B, L, K and S activity was disclosed (e.g. compound 4, Figure 2 , Table 1 ). In LLC (exemplified by 6) were stated to have IC 50 < 50 nM against cruzipain and falcipain. However, no specific biological data was presented [209] . Medivir UK Ltd also published an application with 27 amide-based CPI claimed to be useful for protozoal infections [210] . The in vitro cathepsin S, L and K inhibitory activity, and cathepsin K and falcipain proteolytic catalytic activity of 27 compounds (e.g. 7) were determined but no biological data was presented. Over 450 novel nitrile compounds . These derivatives were claimed to inhibit 13 enzymes of the serine peptidase, cysteine protease, metalloprotease and endopeptidase families and to be useful against the development and metastases of malignant tumors [215] . Finally, Actelion Pharmaceuticals described a series of amino-aza-cycloalkane derivative as inhibitors of aspartic proteases, particularly of the plasmodium falciparum plasmepsin II, useful against protozoal infections. Compound 13, which is one of 140 derivatives disclosed, inhibited plasmepsin II with IC 50 = 18 nM [216] . The synthesis of 5-amino-1-benzyl-imidazole derivatives with distinctive antibacterial, anti-fungal and antitrypanosomal activity was disclosed by Yale University [217] . These compounds were designed as inhibitors of C-14α-demethylase. This enzyme is a cytochrome P450 enzyme (P-450 14DM ) that catalyses the removal of the 14α methyl carbon (C32) of lanosterol in the presence of molecular oxygen and NADPH. Since 14-methyl sterols cannot function within cell membranes, inhibition of P-450 14DM represents a good target for chemotherapy. All of the compounds were tested against T. cruzi amastigotes (Tulahuen strain) grown on monolayer of mouse 3T3 fibroblasts and were non toxic to these cells. The SAR study resulting from the analysis of 40 derivatives put into evidence the importance of hydrophobic substitution and para phenyl substitution (vs. ortho or meta) for better activity. EC 50 values ranged from the remarkable 500 pM (14, Figure 4 ) to 1 µM. However, these compounds had benzoate ester or amide moieties which could potentially be cleaved in vivo by esterase and proteases, affording the less potent free benzoic acid derivatives. Further SAR studies showed that the new scaffold containing an aminobiphenyl moiety (15: IC 50 = 10 nM), although 20-fold less potent than its methyl ester counterpart 14, was more active in vivo. Compound 15, at twice daily 50 mg/kg doses, caused a suppression of parasitaemia in mouse blood within 45 days. Survival of mice treated with 15 was > 100 days whereas control mice died within 20 days. The authors suggested that the phenylbenzylimidazole moiety dominates the interaction with P-450 14DM resulting in inhibition of the enzyme and consequent anti-parasitic activity. However, no data of enzymatic inhibition was reported.
Protein farnesyl transferase inhibitors
Protein prenylation by attachment of polyisoprenoids to specific proteins is involved in signal transduction and anchorage of protein to cell membranes. Protein farnesyl transferase (PFT) inhibitors are potent antitumor agents in experimental animals [58, 59] and few molecules have been assayed in phase II clinical trials for the treatment of human malignancies [60] . Different studies have demonstrated the existence of this process in trypanosomatids and validated PFT inhibitors as an antitrypanosomal chemotherapeutic target [13, 61] . T. brucei and T. cruzi PFT have been cloned and their homology to human and rat orthologues compared. This study revealed significant differences between the active site of T. brucei PFT and its mammalian counterpart (i.e. rat enzyme), suggesting that selective inhibition of the parasite enzyme was possible [61] . For these reasons, PFT inhibitors, whose medicinal chemistry and pharmacokinetics are well defined already, have potential to become interesting antitrypanosomal molecules. Assay. In vitro growth inhibition of T. brucei ranged between 0.2 µM to < 10 µM.
DNA modulating agents (DNA binders, Tubulin inhibitors)
The most promising patent in term of near-future outcome for the treatment of Both of these molecules also cured the STIB900 strain of T. b. rhodesiense in a mouse model and the methoxime prodrug 22 yielded parasite free mice in the CNS model through day 120. As a whole, the methoxime prodrug was consistently more active than the amidoxime and aza-analogues showed superior oral activity in vivo compared to furamidine analogues [62] . Compound 22 was claimed to be useful as an oral treatment of CNS stage HAT [220] . A scalable and more economic procedure for the synthesis of DB-289 and related bis-aryl diamidoxime derivatives was disclosed in another patent by the same group. This methodology used 2,5-bis-trialkylstannanes and a one step palladium-catalyzed cross reaction to form the products [221] . cruzi, with an activity comparable to that of benznidazole. However, no specific data was reported in the patent [222] . Detailed biological data on the activity of these dicationic derivatives against T. cruzi and L. donovani was reported in 2003 [69] . The most active molecules belong to the reversed amidine series, with the most potent compound against T. cruzi having an IC 50 value of 0.15 µM (24, Figure 5 ) with a selectivity index (SI) of 48. mg/kg ip dose. Thus, issues regarding pharmacokinetics and possible toxicity due to nitroaromatic groups need to be addressed in order to fully assess the potential of these molecules.
Purines and pyrimidine metabolism
Purine and pyrimidine nucleotides are essential bricks for the synthesis of DNA and RNA. Trypanosomes, unlike their mammal hosts, lack of de novo purine biosynthesis pathway. Hence, they are dependent on purine salvage from their host medium in order to get these building blocks essential for their survival [80] . An important enzyme of the purine salvage pathway that has been used as a potential target for chemotherapy is hypoxanthine-guanine phosphoribosyl transferase (HGPRT) [13] .
The potential of allopurinol (4-hydroxypyrazol-[3,4-D]pyrimidine) and derivatives to act as a "subversive substrate" of this enzyme was discovered by Marr and colleagues [81, 82] . More attention has been paid recently to the potential of pyrimidine metabolism as chemotherapeutic target in parasites. Trypanosomes are able to synthesise uridine 5'-triphosphate nucleotide (UTP) de novo and by salvage of uracil. The enzyme dUTPase (deoxyuridine 5'-triphosphate nucleotide-hydrolase), which catalyses hydrolysis of dUTP to dUMP and pyrophosphate, is essential for the biosynthesis of dTTP (from UMP via thymidylate synthase) and for maintaining the integrity of genomic DNA [83] .
Trypanosomal dUTPases possess a distinct tridimensional structure and have been proposed as potential targets for chemotherapy [83, 84] . Recently, a series of triphenyl deoxyuridine derivatives selective for plasmodium dUTPase and with in vitro antimalarial activity were described [85] . The in vivo assays with both compounds showed a relapse of trypanosomes after the treatment was stopped, making the authors suggest that these molecules only block the proliferation of the parasites and that an immune response may be required to eradicate the parasites. A patent related to this invention was disclosed by these authors [224] .
They claimed the use of a combination of a CTP synthetase inhibitor, such as a glutamine analogue, and a nucleobase (hypoxanthine, adenine or guanine) able to alleviate the toxic effects thereof in vivo, for the treatment of malaria, leishmaniasis, Chagas' disease and sleeping sickness. The combination of DON (27) and hypoxanthine was preferred.
Natural product derived chemotherapeutic agents
Natural products derived from plants and animals continue being the major source of medicines for man and the basis of many pharmaceutical drugs. In the area of tropical medicine in particular, widely used antiprotozoal drugs derive from natural products. Quinine, an alkaloid extracted from the cinchona trees (Rubiaceae) found in South America and the East Indies, and artemisinin, a sesquiterpene lactone from Artemisia annua (Asteraceae) have been used by traditional medicine to treat malaria. also displayed selectivity (SI > 40) towards the parasite with cytotoxicity on L6-cells > 439 µM [226] . These compounds were also claimed to be potentially useful for the treatment of neurodegenerative diseases based on their glutamate receptor antagonistic activity. The same team described a series of chiral 1-phenyl-2-aminomethyl-naphtalene derivatives for the same indications [225] . The activity of seven compounds was disclosed, being trifluoromethanesulfonate derivative 30 the most interesting one in terms of activity (IC 50 = 1.9 µM) and selectivity (SI > 36).
Antidesmone ( 
Miscellaneous
In a 2004 patent, the Institut de Recherche pour le Développement disclosed the use of canthin-6-one (33), extracted from a Zanthoxylum chiloperone of the angustifolium variety, for the treatment of T. cruzi infections [229] . Canthin-6-one had been previously tested against P. falciparum [92] or Leishmania spp. [93] but its trypanocidal activity had never been reported. This application shows that this natural product is a highly effective trypanocide in the mouse model of Chagas' disease.
Canthin-6-one was assayed in chronic and acute mouse models by oral and subcutaneous administration. In the model of acute T. cruzi infection, in a 15 days treatment at an oral dose of 5 mg/kg/day (n = 7), canthin-6-one was more effective than benznidazole (50 mg/kg/day po, n = 8) at day 15 post-treatment and, contrary to benznidazole, the parasites were eradicated at day 68. In the chronic mouse model, in a 20 days treatment at 5mg/kg/day po, canthin-6-one was again more effective than benznidazole (50 mg/kg/day) after a 79 days post-treatment follow-up. The mice treated with canthin-6-one (n = 8) were parasite free and protected from death [229] .
Lignans obtained from leaves of Zanthoxylum naranjillo or Piper cubeba such as (-)-cubebin, (-)-methylpluviatolide [94] , and semi-synthetic dibenzylbutyrolactonic derivatives were claimed as useful for the treatment and prophylaxis of Chagas' disease [228] . The process to obtain these compounds was disclosed and the in vitro antiChagas disease evaluation of seven compounds was reported (Figure 7) . In an assay University of California disclosed a method for the isolation and purification of marine pseudopterosin compounds from Symbiodinium spp. symbionts, preferably obtained from the coral Pseudopterogorgia elisabethae [230] . This method has the advantage of using a non-animal source for the production of these molecules.
Pseudopterosin A (36) is one of the 18 pseudopterosin compounds specifically claimed for preparation and for use as chemotherapy. However, no biological data was reported for that application. Another class of natural products derived from marine sponges, manzamine alkaloids, were claimed for use in the treatment of drug-resistant infections including malaria and sleeping sickness [232] . Several semi-synthetic derivatives prepared from manzamine A were described. 
Single synthetic entities
This section includes patents describing the synthesis and screening of compounds against several pathogenous agents, including protozoa. No specific targets were claimed to explain the trypanocidal activity of these molecules.
Bicyclic carbohydrates for the treatment of parasitic diseases such as leishmaniasis and trypanosomiasis were disclosed by Kemin Pharma Europe [234] . Three compounds were specifically claimed. Their synthesis and in vitro activity against T. b. rhodesiense, T. cruzi, P. falciparum and L. donovani was disclosed. One compound (39, Figure 8 
